drugset / Trial / NCT00351546

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

NCT00351546

Phase 3 Completed 12 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vildagliptin on insulin sensitivity in people with type 2 diabetes.

Timeline

Start
2005-02
Primary completion
2005-11
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified